Intentional Swallowing

Intended to Deter Swallowing Excess Quantities of Tablets

Aversion® Technology opioid product candidates also include niacin, an active ingredient in vitamins, cholesterol reducers and nutritional supplements, in amounts determined by us to be well tolerated when our product candidates are administered at recommended doses.  We believe physicians, nurses, and other health care providers recognize niacin’s well established safety profile in long term administration at doses far exceeding the amounts in each product candidate utilizing Aversion® Technology. Prospective drug abusers may swallow excess quantities of tablets beyond the amount intended for analgesia to induce euphoria.  Aversion® Technology products are intended to induce temporary dysphoric effects as increasing numbers of tablets are swallowed above the recommended dose.  We believe that should a person swallow excess quantities of tablets utilizing Aversion® Technology they will experience an unpleasant combination of symptoms, including warmth or flushing, itching, sweating and/or chills, headache and a general feeling of discomfort as a result of the increasing dose of niacin.  We believe the undesirable niacin effects at escalating doses will not prevent, but are expected to deter, swallowing excess quantities of Aversion® Technology product candidates.